SCHEMBL6534729

SCHEMBL6534729

CCCCc1nc(Cl)c(C(=O)Cc2ccc(-c3ccccc3C(=O)O)cc2)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 3/20 0.57
AGTR1 P30556 3/20 0.55
AGTR2 P50052 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9558709 0.82 BRS3 (0.50) BRS3
SCHEMBL8330248 0.79 AGTR1 (0.43) BRS3AGTR1AGTR2
SCHEMBL9251216 0.76 AGTR1 (0.36) AGTR1AGTR2
SCHEMBL3906504 0.75 BRS3 (0.70) BRS3AGTR1AGTR2
SCHEMBL8060271 0.75 BRS3 (0.59) BRS3AGTR1AGTR2
SCHEMBL9529409 0.74 BRS3 (0.55) BRS3AGTR1AGTR2
SCHEMBL9025369 0.74 RIPK1 (0.42) AGTR1AGTR2
SCHEMBL1227544 0.74 BRS3 (0.55) BRS3AGTR1AGTR2
SCHEMBL9304542 0.73 BRS3 (0.56) BRS3AGTR1AGTR2
Hexane SCHEMBL9090054 0.73 LTB4R2 (0.64) BRS3AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP claimed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO claimed
EP-0533840-A1 TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS. DU PONT (US) 1993-03-31 EP claimed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 EP claimed
EP-0754042-A4 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO INC (US) 2004-06-23 EP disclosed
EP-1059843-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2000-12-20 EP disclosed
WO-1999043210-A1 METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 1999-09-02 WO disclosed
EP-0754042-A1 TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES MERCK & CO. INC. (US) 1997-01-22 EP disclosed